戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 Ki compared with WT RGS2 in a flow cytometry competition binding assay).
2  independently our results with a minicircle competition binding assay.
3 -347, Lys-351, and Lys-414 was verified by a competition binding assay.
4 ed and validated a fluorescence polarization competition binding assay.
5 oluble Lf receptor activity as determined by competition binding assay.
6 d for their capacity to bind protein using a competition binding assay.
7 ity of LY2795050 was measured in radioligand competition binding assays.
8  (hD3) receptor (Ki = 1-5 nM) as measured in competition binding assays.
9 as observed by coprecipitation, overlay, and competition binding assays.
10  higher than their respective Ki values from competition binding assays.
11 sing ELISA, immunohistochemical studies, and competition binding assays.
12 er of potency comparable to that observed in competition binding assays.
13                                           In competition-binding assays, A-204197 competed with [3H]-
14 ma (PPARgamma), we identified GW9662 using a competition binding assay against the human ligand bindi
15  employed in an automated fluorescence-based competition binding assay, allowing the pKi values of se
16 Evolution of pRNA aptamers was followed by a competition binding assay and nucleotide sequencing, and
17  to GPIIb/IIIa receptors was investigated in competition binding assays and autoradiography using a f
18                           Here, we have used competition binding assays and peptide binding assays to
19 ntagonists between the beta-lactamase assay, competition-binding assay, and other direct measurements
20                                              Competition binding assays at several serotonin receptor
21                                Self-exchange competition binding assays between fluorescently labeled
22                                    The Blitz competition binding assay confirmed target binding of NU
23                                         In a competition binding assay, DAB4 bound EL4 murine thymic
24                                              Competition binding assays demonstrate that this binding
25                                     In vitro competition binding assays demonstrated that 1-4 have a
26                                     In vitro competition binding assays demonstrated that compounds 9
27          In vitro screening with radioligand competition binding assays demonstrated variable affinit
28 eta oligomer preparations makes conventional competition binding assays difficult to interpret.
29 ated PRP, and 4 nM in solid-phase GPIIb-IIIa competition binding assay (ELISA).
30 ed in vitro in a transactivation assay and a competition binding assay for all RARs.
31 trategy for developing an optimal FRET-based competition binding assay for tyrosine kinases.
32                                           In competition binding assays FXI/PKA4, FXI/PKA4-Gly326, an
33 [N-methyl]-[(3)H]scopolamine methyl chloride competition binding assay in the presence of GTP.
34 d their binding affinities were evaluated in competition binding assays in HEK 293 cells transfected
35 ide was also shown to be highly selective in competition binding assays in rat brain membranes.
36 to all five human receptors using direct and competition binding assays in solution.
37                                   A solution competition binding assay, in which a surface immobilize
38 n significantly activate the AHR, and ligand competition binding assays indicate that I3S is a direct
39                                              Competition binding assays indicate that the binding of
40                                    Classical competition binding assays measure the binding of a labe
41 onists in [3H]5'-N-ethylcarboxamidoadenosine competition binding assays performed with yeast cell mem
42                                              Competition binding assays reveal that U2 snRNA (the hig
43                                            A competition binding assay revealed a dissociation consta
44                                              Competition binding assays revealed that the anti-SEE an
45                                           In competition binding assays, SET knockdown increased high
46                                              Competition binding assays show minimal dissociation of
47                                              Competition binding assays showed 11-25 and 27-31 bound
48  combined with cross-linking experiments and competition-binding assays showed that the fully disorde
49                                 Furthermore, competition binding assays suggest that Q509L decreases
50                                            A competition binding assay suggested a direct interaction
51             The pharmacological profile from competition binding assays suggests that the ligands may
52  analysis and/or by [125I]alpha-bungarotoxin competition binding assays the interactions of acetylcho
53                                           In competition binding assays, the affinity of agonists is
54 ing affinity but similar to those shown in a competition binding assay to displace radioiodinated ana
55                               In equilibrium competition binding assays to membranes from Sf9 cells i
56   We demonstrate the use of a DNA minicircle competition binding assay, together with DNA cyclization
57 nitor C protein-oligonucleotide binding in a competition binding assay under equilibrium conditions.
58                                         In a competition binding assay using the p85 PI 3-kinase C-te
59 ng was assessed in mobility shift assays and competition binding assays using cisplatin-damaged DNA.
60            Binding affinity was measured via competition binding assays using hB1R-expressing Chinese
61                         BIAcore analysis and competition binding assays using LOX human malignant mel
62 s and pharmacokinetic studies in mice and in competition binding assays using recombinant, soluble Fc
63                                              Competition binding assays using stably transfected L293
64 68, and (nat)Ga-JMV5132 were determined in a competition-binding assay using GRPR-overexpressing PC-3
65                                      Using a competition binding assay, we have established that Klen
66                                      Using a competition binding assay, we show that the affinity of
67                                        Using competition binding assays, we find that short C-termina
68                                        Using competition binding assays, we further characterized thi
69             Using GW2331 as a radioligand in competition binding assays, we show that certain mono- a
70 etic resonance spectroscopy and protein-drug competition binding assays were employed to define the g
71                                              Competition binding assays were employed to examine the
72                                 A BRET-based competition binding assay with 4 was also established an
73 e (Mr approximately 250-500 Da) ligands in a competition binding assay with cyclosporin A (CsA).
74                                              Competition binding assays with [(3)H]MRS2279 and P2Y1-R
75                                              Competition binding assays with b12 also showed that b12
76 tudy ligand-protein interactions by coupling competition binding assays with mass spectrometry-based
77 ant (C1)4 and (C2)4 homotetramers along with competition binding assays with poly(A) and poly(C) indi
78               Selected probes were tested in competition binding assays with unlabeled competitors in

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。